Search

Your search keyword '"Satomi Morita, MD"' showing total 2 results
Start Over Author "Satomi Morita, MD" Publication Year Range Last 50 years
2 results on '"Satomi Morita, MD"'

1. Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study

Author

Yuki Katayama, MD, PhD, Tadaaki Yamada, MD, PhD, Kenji Morimoto, MD, PhD, Hiroyuki Fujii, MD, Satomi Morita, MD, PhD, Keiko Tanimura, MD, PhD, Takayuki Takeda, MD, PhD, Asuka Okada, MD, PhD, Shinsuke Shiotsu, MD, PhD, Yusuke Chihara, MD, PhD, Osamu Hiranuma, MD, Takahiro Yamada, MD, PhD, Takahiro Ota, MD, PhD, Taishi Harada, MD, Isao Hasegawa, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Noriyuki Tanaka, MD, PhD, Aya Miyagawa-Hayashino, MD, PhD, and Koichi Takayama, MD, PhD

Subjects
Chemoimmunotherapy, PD-L1, Non–small cell lung cancer, Prospective analysis, Therapeutic response, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Introduction: Multiple programmed death-ligand 1 (PD-L1) immunohistochemistry assays performed using different antibodies including DAKO 22C3, DAKO 28-8, and Ventana SP142 PD-L1—predictive markers for response to various immune checkpoint inhibitors in NSCLC—have been approved in several countries. The differences in multiple PD-L1 immunohistochemistry assay results in predicting the therapeutic response to combined chemoimmunotherapy in patients with NSCLC remain unclear. Methods: In this multicenter prospective observational study, we monitored 70 patients with advanced NSCLC treated with combined chemoimmunotherapy at 10 institutions in Japan. The expression of PD-L1 in pretreatment tumors was evaluated using the 22C3, 28-8, and SP142 assays in all patients. Results: The PD-L1 level in tumor cells determined using the 22C3 assay was the highest among the three assays performed with different antibodies. According to the 22C3 assay results, the PD-L1 tumor proportion score greater than or equal to 50% group had a significantly longer progression-free survival period than the PD-L1 tumor proportion score less than 50% group. Nevertheless, the other assays did not reveal remarkable differences in the objective response rate or progression-free survival. Conclusions: In our study, PD-L1 expression determined using the 22C3 assay was more correlated with the therapeutic response of patients with NSCLC treated with combined chemoimmunotherapy than that determined using the 28-8 and SP142 assays. Therefore, the 22C3 assay may be useful for clinical decision-making for patients with NSCLC treated with combined chemoimmunotherapy. Trial registration number: UMIN 000043958.

Published
2024
Full Text
View/download PDF

2. TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study

Author

Yuki Katayama, MD, Tadaaki Yamada, MD, PhD, Kenji Morimoto, MD, PhD, Hiroyuki Fujii, MD, Satomi Morita, MD, Keiko Tanimura, MD, PhD, Takayuki Takeda, MD, PhD, Asuka Okada, MD, PhD, Shinsuke Shiotsu, MD, PhD, Yusuke Chihara, MD, PhD, Osamu Hiranuma, MD, Takahiro Yamada, MD, PhD, Takahiro Ota, MD, PhD, Taishi Harada, MD, Isao Hasegawa, MD, PhD, Akihiro Yoshimura, MD, PhD, Masahiro Iwasaku, MD, PhD, Shinsaku Tokuda, MD, PhD, Young Hak Kim, MD, PhD, and Koichi Takayama, MD, PhD

Subjects
Combined chemoimmunotherapy, Thyroid transcription factor 1, Lung adenocarcinoma, Prospective observation study, PD-L1, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Introduction: Lung adenocarcinoma with negative TTF-1 expression is believed to be a poor prognostic factor for certain systemic treatments. Nevertheless, the impact of TTF-1 expression on combined chemoimmunotherapy remains unclear. We aimed to investigate the relationship between tumor TTF-1 expression and the efficacy of combined chemoimmunotherapy in patients with advanced lung adenocarcinoma. Methods: This multicenter prospective observational study included 58 patients with advanced lung adenocarcinoma treated with combined chemoimmunotherapy across 10 institutions in Japan. The expression of TTF-1 in pretreatment tumors was determined using immunohistochemistry. Results: The objective response rate of combined chemoimmunotherapy was significantly higher in TTF-1–positive groups than in TTF-1–negative groups (p = 0.02). The median progression-free survival (PFS) and overall survival were significantly longer in TTF-1–positive groups than in TTF-1–negative groups (10.9 versus 5.0 mo; p = 0.01). Multivariate analysis revealed that TTF-1 expression was an independent favorable prognostic factor for PFS. Moreover, TTF-1 expression in patients with lung adenocarcinoma is significantly associated with programmed death-ligand 1 expression (p = 0.003). The TTF-1–positive group with programmed death-ligand 1 tumor proportion score greater than or equal to 50% had a significantly longer PFS than the other groups (p = 0.02). Conclusions: TTF-1 positivity is associated with better clinical outcomes in patients with advanced lung adenocarcinoma treated with combined chemoimmunotherapy.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results